Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNG1153
- Development stage
- Unknown
- Lead developer
- Shenogen Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SNG1153 (also known as Fukelading) is a small molecule inhibitor developed by Beijing Shenogen Pharma Group. It is currently in Phase 1 clinical development for the treatment of liver carcinoma and lung cancer. The drug is specifically designed to target and inhibit lung cancer stem/progenitor cells, which are a subpopulation of tumor cells associated with chemoresistance, metastasis, and disease recurrence. SNG1153 is part of Shenogen's broader research program focusing on the modulation of the estrogen receptor alpha variant ERα36 and related signaling pathways, such as the IL-6/Jak2/Stat3 axis, to suppress tumor growth and stemness in solid malignancies.
- Other names
- 氟可拉定Fukelading
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)ERα36 (ER-alpha36)NF-κBSTAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on SNG1153.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNG1153.